Drug Discovery@nature.com 21 June 2013

TABLE OF CONTENTS 21 June 2013 News Analysis Research Highlights Research & Reviews Careers Nature Reviews Drug Discovery is on Twitter Advertisement SciBX: Science Business eXchange Innovation in Drug Discovery Challenge: Harnessing Endocytosis for Drug Discovery SciBX, in partnership with Innocentive, is requesting ideas from the scientific community to progress the understanding of how large therapeutic molecules can effectively intercept and use the endocytosis process to achieve class-wide cell permeability.   Click here to find out more!       News Top ‘Master protocol’ aims to revamp cancer trials doi:10.1038/498146a Pilot project will bring drug companies together to test targeted lung-cancer therapies. Full Text Brain scan predicts best therapy for depression doi:10.1038/nature.2013.13183 Researchers find first potential biomarker for guiding treatment choice. Full Text SGLT2 inhibitors enter crowded diabetes space doi:10.1038/nbt0613-469 Two drugs in a new class of therapies for type 2 diabetes have recently been approved. Full Text Heavy drugs draw heavy interest from pharma backers doi:10.1038/nm0613-656 The idea of using deuterium substitution to improve the metabolic properties of drugs is garnering interest. Full Text Analysis Top Personalizing cystic fibrosis in vitro doi:10.1038/scibx.2013.564 A new rapid and quantitative in vitro intestinal cell–based assay for function of cystic fibrosis transmembrane conductance regulator could help identify prospective responders to targeted cystic fibrosis therapies. Full Text RON's new role doi:10.1038/scibx.2013.507 A team has shown that inhibiting the kinase RON could fight cancer metastasis by stimulating an antitumour immune response, building a case for focusing drug discovery efforts specifically against RON, which has long been neglected in favour of its relative, MET. Full Text Research Highlights Top Inflammatory disorders: Targeting TRAFs tames inflammation doi:10.1038/nrd4029 Inhibition of tumour necrosis factor receptor-associated factors (TRAFs) through FBX03 could represent a novel potential anti-inflammatory therapeutic strategy. Full Text G protein-coupled receptors: Pioneering Frizzled family receptor structure solved doi:10.1038/nrd4030 A crystal structure of the human Smoothened (SMO) receptor — an essential component of the Hedgehog signalling pathway — bound to an antitumour compound has been solved. Full Text Analgesia: A new player in neuropathic pain pathogenesis doi:10.1038/nrd4031 The WNT family of proteins, which are involved in the regulation of cellular processes during nervous system development, have a key role in the pathogenesis of neuropathic pain. Full Text Research & Reviews Top Advances in the development of nucleoside and nucleotide analogues for cancer and viral diseases doi:10.1038/nrd4010 Although nucleoside analogues have been used clinically for decades, efforts continue to improve response rates and reduce side effects. This article highlights recent progress in the development of new nucleoside and nucleotide analogues for cancer and viral diseases. Full Text The emerging mutational landscape of G proteins and G-protein-coupled receptors in cancer doi:10.1038/nrc3521 This article discusses deep sequencing studies indicating that nearly 20% of human tumours harbour mutations in G-protein-coupled receptors (GPCRs) and the implications for GPCRs as therapeutic targets in oncology. Full Text The good, the bad and the ugly — TFH cells in human health and disease doi:10.1038/nri3447 An increasing number of studies have highlighted new aspects of the differentiation and function of T follicular helper (TFH) cells in disease, which might represent targets for novel therapeutics. Full Text Small molecule inhibition of the KRAS–PDEδ interaction impairs oncogenic KRAS signalling doi:10.1038/nature12205 Interfering with binding of PDEδ to KRAS with small molecules provides a novel opportunity to suppress oncogenic RAS signalling by altering its localization to endomembranes. Full Text Drug Discovery JOBS of the week Postdoctoral Fellow — Drug Discovery / GU Oncology Moffitt Cancer Center & Research Institute Medicinal Chemist University of Dundee, College of Life Sciences Postdoctoral Fellow / Research Scientist (Organic Chemist) Institute of Bioengineering and Nanotechnology (IBN) A PhD student position available for Chemist at CNIC Spanish National Cardiovascular Research Center (CNIC) Research Fellow in Medicinal Chemistry University of Michigan Medical School More Science jobs from Drug Discovery EVENT Comprehensive Overview of FDA Regulatory Compliance for Drug and Biotech Products 19.-20.09.13 Berlin, Germany More science events from Careers Top Career snapshots archive Career snapshots feature people associated with drug discovery and drug development, with the aim of providing expert insights and advice on a wide range of positions and career paths in this field. Full Text Top Natureevents is a fully searchable, multi-disciplinary database designed to maximise exposure for events organisers. The contents of the Natureevents Directory are now live. The digital version is available here. Find the latest scientific conferences, courses, meetings and symposia on natureevents.com. For event advertising opportunities across the Nature Publishing Group portfolio please contact natureevents@nature.com More Nature Events

You have been sent this Table of Contents Alert because you have opted in to receive it. You can change or discontinue your e-mail alerts at any time, by modifying your preferences on your nature.com account at: www.nature.com/myaccount (You will need to log in to be recognised as a nature.com registrant) For further technical assistance, please contact our registration department For print subscription enquiries, please contact our subscription department For other enquiries, please contact our customer feedback department Nature Publishing Group | 75 Varick Street, 9th Floor | New York | NY 10013-1917 | USA Nature Publishing Group's worldwide offices: London - Paris - Munich - New Delhi - Tokyo - Melbourne San Diego - San Francisco - Washington - New York - Boston Macmillan Publishers Limited is a company incorporated in England and Wales under company number 785998 and whose registered office is located at Brunel Road, Houndmills, Basingstoke, Hampshire RG21 6XS. © Nature Publishing Group, a division of Macmillan Publishers Limited. All Rights Reserved.